NCT05303376View on ClinicalTrials.gov

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

IBIO123

5 or 10 mg

OTHER

Placebo

matching placebo

Trial Locations (5)

10002

"Hospital №1 of the Zhytomyr City Council", Zhytomyr

76000

Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk

76018

City Clinical Hospital #1 of Ivano-Frankivsk City Council, Ivano-Frankivsk

0157

JOHESE UNITAS Hospital, Lyttelton

0002

JOHESE ZAH Hospital, Pretoria

Sponsors
All Listed Sponsors
lead

Immune Biosolutions Inc

INDUSTRY